Quantum Computing Inc. Set to Join Russell 2000® and Russell 3000® Indexes
HOBOKEN, N.J., May 29, 2025 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), an innovative, integrated photonics and quantum optics technology company, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, May 23, 2025.
The broad-market Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000 Index is a subset of the broader Russell 3000 Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025 this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Chris Boehmler, Chief Financial Officer of QCi, commented, "We're pleased to announce the inclusion of QCi in the Russell 3000® and Russell 2000® Indexes, marking a meaningful milestone in our growth. This inclusion expands our visibility among a broader pool of institutional investors and index funds and reflects the progress we've made in strengthening our financial foundation while advancing quantum technologies with real-world applications."
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.
About Quantum Computing Inc.
Quantum Computing Inc. (Nasdaq: QUBT) is an innovative, integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines and TFLN foundry services to the world today. QCi's products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer unique capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell.
QCi Company Contact:Rosalyn Christian/John NesbettIMS Investor Relationsqci@imsinvestorrelations.com
Forward-Looking Statements
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, generally identified by terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," "aim to," or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including the growth rate of the market, timing of revenue recognition and our ability to innovate and deliver products, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quantum-computing-inc-set-to-join-russell-2000-and-russell-3000-indexes-302468076.html
SOURCE Quantum Computing Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech
Eli Lilly has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company's legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the pharmaceutical sector. The company's ongoing talks to acquire Verve Therapeutics also show its commitment to growing its gene-editing capabilities. These events have added weight to the broader market's trends. We've identified 2 warning signs for Eli Lilly (1 can't be ignored) that you should be aware of. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Recent developments at Eli Lilly, such as the RyboDyn Inc. collaboration, have potential implications for its strategic growth, particularly in precision immunotherapies. This aligns with the company's narrative of expanding capabilities in oncology and immunology, indicating possible enhancements in revenue and earnings forecasts over the long term. Additionally, as Eli Lilly progresses with Phase III trials, including those for orforglipron, the anticipated product approvals could bolster revenue avenues by tapping into high-demand markets like diabetes and obesity treatments. Over the past five years, Eli Lilly's total shareholder return was a very large 430.14%, demonstrating substantial long-term growth despite recent underperformance against the US Pharmaceuticals industry, which saw a 8.9% drop over the past year. This impressive five-year return provides context to the company's current position, underscoring a history of robust shareholder value creation. Given the ongoing acquisition talks with Verve Therapeutics and Eli Lilly's significant investment in both manufacturing and R&D, the outlook for future revenue and earnings remains optimistic. However, potential regulatory hurdles and pricing pressures, particularly in the U.S. market, highlight possible challenges. The shares, with a current price of US$775.12, are 21.0% below the analyst consensus target of US$981.63. This discount suggests room for growth, should the company meet or exceed the analyst expectations on revenue and earnings. Learn about Eli Lilly's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
Stellantis Evaluates Maserati's Future, Including Potential Sale -- Reuters
Stellantis (STLA, Financials) is weighing a possible sale of its luxury brand Maserati as part of a broader strategic review, according to a Reuters report citing two unnamed sources familiar with the matter. Warning! GuruFocus has detected 11 Warning Signs with STLA. The discussions reportedly began before newly appointed CEO Antonio Filosa officially takes the helm. Maserati's future is under review as Stellantis navigates a shrinking U.S. market, Chinese competition, and steep tariffs imposed by President Donald Trump on foreign-made cars and parts. Despite the internal review, a Stellantis spokesperson told Reuters that Maserati is not for sale. McKinsey declined to comment. Maserati's sales fell by over 50% last year to 11,300 units, with no new models currently scheduled for launch. A new business plan is expected once Filosa begins his tenure. Stellantis' board remains split on the brand's futuresome directors reportedly view Maserati as a reputational asset, while others believe it lacks viability for a sustainable relaunch. Analysts say streamlining Stellantis' 14-brand portfolio could improve profit margins. The company's shares have lost roughly two-thirds of their value since March 2024. Chinese automakers such as Chery could emerge as potential buyers, echoing earlier moves like Geely's acquisition of Volvo or SAIC's purchase of MG. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
How Advisors Can Avoid Becoming Over-Reliant on AI
Apparently there's no AI in team. Artificial intelligence is being hailed as a key element of the fourth industrial revolution, and new tools are now assisting financial advisors with taking notes, drafting emails, and brainstorming thought leadership content. In fact, the vast majority of advisors said generative AI helped their practices, according to a survey earlier this year. But AI isn't a silver bullet. It lacks emotional intelligence and a human touch. Advisors risk damaging client relationships if they become too reliant on automation — even for routine tasks. 'AI is poor at empathy so far,' said Adrian Johnstone, CEO of the CRM platform Practifi. 'Advisors need to recognize where the personal connection is most powerful, and use AI to automate and alleviate the lesser functions.' READ ALSO: What the GENIUS Act Means for Stablecoins and Advisors and Why UBS Is the Only Wirehouse to Allow Podcasting Today, most advisors use AI to boost meeting efficiency and streamline workflows. Ideally, this frees up more time to spend with clients, but misusing these tools can backfire. 'The common refrain of disaffected clients is: 'I pay you to understand me, my goals, and my fears, not to outsource me to a machine,'' Johnstone said. Wealth management is built on bespoke service, but AI hasn't yet learned to fully adapt to individual client needs and goals. While tools that draft emails and website content are improving, the output still reads 'hollow and generic,' Johnstone warned. Use it or Lose it. Client-facing AI tools can be 'extremely risky' because they can't interpret emotional undertones of client's concerns, said Rafael Loureiro, CEO of an estate planning platform. Still, AI can be useful for quick, factual tasks. 'If it's midnight on a Sunday and a client asks, 'What was my marginal tax rate last year?' that's a perfect use case,' Loureiro said. 'It's not doing financial planning, but answering factual questions.' Everything in Moderation. This isn't the first time new tech or strategies meant to disrupt the wealth management industry have wound up causing trouble for advisors and their clients. Will Trout, director at Datos Insights, pointed to the 2008 financial crisis as a warning. 'Firms that over-relied on risk models without human oversight suffered catastrophic losses,' he told Advisor Upside. This post first appeared on The Daily Upside. To receive financial advisor news, market insights, and practice management essentials, subscribe to our free Advisor Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
